Insights From Building a New National Cancer Institute Community Oncology Research Program Site

Thomas Saphner, MD; Michael A. Thompson, MD, PhD; Sara Planton, BSN; Maharaj Singh, PhD; Neha Glandt, BA; Lisa Robinson, BS; Jan DeBartolo, MSN

ABSTRACT

Background: The new National Cancer Institute (NCI) Community Oncology Research Program (NCORP) went live August 1, 2014; 34 sites were selected for the program, including 7 new sites that previously did not have a research grant from the NCI. This report describes the first year of a new program site.

Methods: Accrual, investigator and site participation, and number of open studies by the program over the first 12 months of the grant were compared to performance at our institution over the prior 12 months.

Results: During the pre-NCORP period, 84 patients were accrued to NCI-sponsored trials and 106 patients to non–NCI-sponsored trials. In year 1 of the new program, 140 were accrued to NCI-sponsored trials—a 66% improvement, and 109 patients to non–NCI-sponsored trials (P = 0.013 when comparing corresponding increases for NCI vs non-NCI trials). Success of the NCI-sponsored trials was associated with increased accrual to both treatment trials (P = 0.03) and Alliance for Clinical Trials in Oncology-sponsored trials (P = 0.0001).

Conclusions: NCORP implementation was associated with a significant (P = 0.013) improvement in accrual to NCI-sponsored trials that was immediate (1 year) and large (a 66% increase in accrual). In year 2, the intention is to increase cancer control studies; foster inclusion of radiation, surgical, gynecologic, and neurologic oncologists; and focus on minority outreach. Studies that accrue poorly will be assessed, and those accruing poorly on a national basis will be considered for closure. Studies accruing well nationally will be evaluated for barriers to local accrual.

INTRODUCTION

In recent years, the National Cancer Institute (NCI) has been challenged to do more research with less funding. Its cooperative groups were merged and all trials consolidated under the National Clinical Trials Network. In addition, the NCT’s 2 community programs, the Community Clinical Oncology Program (CCOP) and the NCI Community Cancer Centers Program were replaced by the NCI Community Oncology Research Program (NCORP).1,2 In August 2014, the NCI announced 34 institutions selected to receive NCORP community site grants. Most of these grants were awarded to sites that previously had a CCOP grant (n = 20) or mergers of multiple sites that previously had CCOP grants (n = 7). However, grants also were awarded to 7 new sites including the Aurora NCORP, which is affiliated with the Milwaukee-based health provider Aurora Health Care.

Prior to being awarded the grant, Aurora was a main site for the National Surgical Adjuvant Breast Project and the Gynecologic Oncology Group and an affiliate site for the Radiation Therapy Oncology Group. 3 national groups that subsequently merged to form NRG Oncology. Aurora also was an affiliate site for Eastern Cooperative Oncology Group—American College of Radiology Research Network. Limited availability to trials from other cooperative groups was available through the Clinical Trials Support Unit.

In this report, the first year of the Aurora NCORP was compared to the year prior to its implementation to determine if there was any change in accrual patterns. The program’s first-year performance also was compared to NCI expectations and the American Society of Clinical Oncology guidelines for excellence in community research.

METHODS

Terminology and Definitions: “NCI-sponsored trials” were defined as trials from any of the NCI-sponsored research bases. “Non–NCI-sponsored trials” were industry-sponsored studies, investigator-initiated studies, and registries managed by the Aurora Research Institute (Milwaukee, Wisconsin) requiring institutional review board (IRB) approval and patient consent.
“Investigators” were identified as physicians who had completed human subjects training in accordance with Aurora IRB requirements and were registered NCI investigators. This report includes investigators who met these requirements any time during the interval specified.

An “open clinical trial” was a trial open to accrual for any portion of time during the interval specified.

**Time Intervals:** August 1, 2013, to July 31, 2014 was the year “prior to NCORP,” “year 1” of the program was August 1, 2014, to July 31, 2015.

**Software and Statistical Analysis:** Via Oncology™ (Via Oncology, Pittsburgh, Pennsylvania) is a clinical decision support program4 that was added to the electronic health record (Epic Systems, Verona, Wisconsin).5 It prioritizes treatment choices by efficacy, followed by toxicity and then cost, and assists medical oncologists with treatment options. The system, which went live at our organization on November 3, 2014,6,7 is configured to prioritize clinical trial options when available.

Patients with cancer were recorded and classified by the Aurora Health Care Cancer Registry. The accrual of patients to clinical trials was calculated based on the total number of new analytical cases recorded for the last complete year.

All categorical variables were described as frequencies and percentages, and comparisons across categories were made using chi-square or Fisher’s exact test as appropriate. When expected frequencies were less than 5, including zero, Fisher’s exact test was used. All continuous variables were described as mean, median, standard deviation (SD), and range of minimum-to-maximum values. Multivariate logistic regression was used to identify predictors of the NCORP accrual. For all statistical tests, alpha ≥ 0.05 was used as level of significance. All statistical analysis was done using SAS version 9.4 (SAS Institute, Cary, North Carolina).

**Monthly Reports:** The NCORP Update is a monthly report e-mailed to all investigators and other members of the clinical trials community (Appendix). It provides accrual metrics categorized by investigator, site, study, research base, and by oncology specialty. It also includes a summary of accrual for month- and year-to-date. The NCORP Open Trials document is updated monthly and sent with the NCORP Update. Both documents are restricted to a single page to encourage routine readership. The monthly program meeting is attended by principal investigators, the program administrator, the clinical trials director and the oncology clinical trials manager. The purpose of the meeting is to provide a forum of regular dialogue regarding program successes, challenges, and needs.

**Research Bases:** Prior to the NCORP, Aurora was a member of Eastern Cooperative Oncology Group – American College of Radiology Research and NRG Oncology. During year 1 of the program, Aurora added the following research bases: Alliance for Clinical Trials in Oncology (Alliance), University of Rochester Cancer Center, and Wake Forest University. The Cancer and Leukemia Group B, American College of Surgeons Oncology Group, and North Central Cancer Treatment Group merged to form the Alliance, whereas the University of Rochester Cancer Center and Wake Forest are research bases with special interest in cancer control research.

**RESULTS**

**Aurora Tumor Registry:** The total number of cancer patients seen from August 1, 2013, to July 31, 2015, was 15,114. Non-Hispanic/non-Latino whites numbered 13,208; minority patients totaled 1,906 (12.6%). Prior to the NCORP, 7,065 new cancer patients were seen compared to an estimated 8,049 new patients in year 1.

**Number of Trials Open, Investigators:** Prior to NCORP, there were 49 NCI-sponsored trials and 30 non–NCI-sponsored trials. During year 1, NCI-sponsored trials increased to 63 and non–NCI-sponsored trials increased to 45. The number of NCI trials open as a percentage of all open trials was not significantly different between the 2 periods (P = 0.61). There were 63 investigators prior to the NCORP and 65 during year 1.

**Accrual Rate to NCI Clinical Trials:** Of the 7,065 patients in the tumor registry, 84 (1.2%) were accrued to NCI-sponsored trials prior to the NCORP vs 140 of 8,065 (1.7%) during year 1.

**Accrual to NCI vs Non-NCI:** Prior to the NCORP, 84 patients were accrued to NCI-sponsored trials and 106 patients to non–NCI-sponsored trials. During year 1, 140 were accrued to NCI-sponsored trials and 109 to non–NCI-sponsored trials. This change was a 66% improvement in accrual to NCI-sponsored trials, which is statistically significant compared to the corresponding increase in non–NCI-sponsored trials (P = 0.013).

**Accrual by Minority Status:** Eight of 84 accruals (10%) prior to the NCORP were minority patients, while 15 of 140 accruals (11%) during year 1 were minority patients (P = 0.8).

**Accrual by Treatment or Cancer Control:** Accrual to treatment trials increased from 72 to 132 after year 1; accrual to cancer control trials dropped from 12 to 8 (P = 0.03), respectively.

**Accrual by NCORP Research Base:** There has been a significant change in accrual by research base (P < 0.0001), except for Wake Forest, which experienced no increase during the study period. The Alliance experienced the greatest increase (from 7 to 46), and the University of Rochester Cancer Center accruals rose from 0 to 5 (Table 1).

**Accrual by Oncology Specialty:** During year 1, medical oncologists increased accruals from 72 to 119; radiation oncologists from 7 to 9, surgical oncologists from 0 to 6, and neurologic oncologists...
Increased accrual also was associated with increased accrual to Alliance-sponsored trials. It is likely this is related to the availability of practical trials for common cancers from the Alliance and increased awareness of these trials after the Aurora program added the Alliance research base.

Increased accrual of minority patients was proportional to increased accrual in general. Relative accrual to minority trials was stable. The percent of minorities enrolled in clinical trials was 10%, while the percent in Aurora’s tumor registry was 12%. This suggests that the highest minority accrual the program is likely to achieve is 12%, and published strategies for improvement of
minority involvement may not result in a decisive increase in accrual. Identification and quantification of minority patients who are not documented in the Aurora tumor registry may be an opportunity for improved minority accrual.

Accrual by investigator was highly variable; 24 of 61 total investigators had no accrual at all. The observation that physicians commonly complete registration to become an investigator and complete human subjects training but fail to accrue patients to trials is not new. Medical oncologists accrued the most patients, followed by radiation oncologists and surgical oncologists, but the changes in accrual pre- and post-NCORP by specialty were not significant at this institution. This distribution of accrual by oncologic subspecialty is consistent with the literature. It has been suggested that a minimum of 4 accruals to NCI-sponsored trials be required to maintain clinical investigator status.18

Accrual by study also was highly variable. Eight of the NCI studies had no accrual for a year, and 5 NCI studies had no accrual for 2 years. Two of these trials are accruing well nationally, and investigation of local barriers is underway. Three of the trials are not accruing well locally or nationally and are candidates for closure.

The mean number of accruals for an open trial at our program was 2.2, but the number of accruals for each open study varied greatly by oncologic subspecialty (range: 0.3-3.3). This could be interpreted as a guide to the types of trials to open to maximize accrual, or as a clue to the specific subspecialties that may have the greatest potential for increased accrual in the future.

Many activities were initiated during year 1 that likely improved accrual, including the initiation of Via Oncology—a clinical decision support program that prioritizes clinical trials, the NCORP Monthly Update, the NCORP Open Trials list, the monthly program meeting, and many others.19,20 These activities were described qualitatively in the Methods section because it is likely they related to increased accrual, but they were not mentioned in the Results section because it was not possible to individually quantify their effects.

The NCORP grant was associated with a large (66%), significant, and immediate (P=0.013 at 1 year) improvement in accrual. Now in its second year, the Aurora NCORP acknowledges the following observations and opportunities:

- Cancer treatment studies historically have been the most successful at Aurora NCORP, but the greatest opportunity for increased accrual is cancer control studies.
- Medical oncologists are central to a successful community research program, but the greatest opportunity for enhanced accrual lies with radiation oncology, surgical oncology, gynecologic oncology, and neurologic oncology trials.
- Minority accrual is close to expected based on our registry data but if there are patients not captured in the registry, they may be a potential source of accrual growth.
- Studies that accrue poorly at the Aurora program and nationally will be closed. Studies that accrued poorly at Aurora but accrue well nationally will be evaluated for local barriers, as they may be a potential source of increased accrual.
Acknowledgements: The authors thank Katie Klein and Joe Grundle for editing assistance.

Funding/Support: NCI Community Oncology Research Program (NCORP) – Community Site, Grant Number: 5U51CA190140-02.

Financial Disclosures: Michael Thompson, MD, PhD, owns stock in Doximity and has a consulting or advisory role in VIA Oncology, AIM Health, Bristol Myers Squibb, MD Ring, and Celgene. All other authors declare no conflict of interest.

REFERENCES


advancing the art & science of medicine in the midwest

WMJ

The mission of WMJ is to provide a vehicle for professional communication and continuing education for Midwest physicians and other health professionals.

WMJ (ISSN 1098-1861) is published by the Wisconsin Medical Society and is devoted to the interests of the medical profession and health care in the Midwest. The managing editor is responsible for overseeing the production, business operation and contents of the WMJ. The editorial board, chaired by the medical editor, solicits and peer reviews all scientific articles; it does not screen public health, socio-economic, or organizational articles. Although letters to the editor are reviewed by the medical editor, all signed expressions of opinion belong to the author(s) for which neither WMJ nor the Wisconsin Medical Society take responsibility. WMJ is indexed in Index Medicus, Hospital Literature Index, and Cambridge Scientific Abstracts.

For reprints of this article, contact the WMJ at 866.442.3800 or e-mail wmj@wismed.org.

© 2016 Wisconsin Medical Society